GENPREX INC. news, videos and press releases
For more news please use our advanced search feature.
GENPREX INC. - More news...
GENPREX INC. - More news...
- Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
- Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
- Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases - Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
- Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
- Genprex to Participate in Upcoming Investor Conference in March
- Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
- Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
- Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
- Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
- Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
- Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
- Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
- Genprex to Present in November CEO Roadshow Webinar
- Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
- Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
- Genprex to Participate in Upcoming May Investor Conferences
- Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
- Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
- Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
- Genprex to Participate in CEO Roadshow Webinar Series
- Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
- Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
- Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
- Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting
- Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
- Genprex to Participate in Upcoming March Investor Conferences
- Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
- Genprex Announces Formation of Clinical Advisory Board
- Genprex Recognizes World Cancer Day
- Genprex Issues Shareholder Letter and Provides Corporate Update
